B. Riley Financial Reiterates “Neutral” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “neutral” rating restated by equities researchers at B. Riley Financial in a research report issued on Monday, Marketbeat reports. They presently have a $10.00 target price on the biotechnology company’s stock. B. Riley Financial’s target price suggests a potential upside of 56.79% from the stock’s current price.

A number of other research firms have also commented on CAPR. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Roth Capital restated a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Finally, LADENBURG THALM/SH SH raised shares of Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.78.

Capricor Therapeutics Stock Down 67.6%

Capricor Therapeutics stock traded down $13.32 during mid-day trading on Monday, reaching $6.38. The company had a trading volume of 14,534,242 shares, compared to its average volume of 1,402,173. The company has a 50 day moving average of $25.29 and a 200-day moving average of $27.48. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a market cap of $369.36 million, a price-to-earnings ratio of -2.79 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, analysts predict that Capricor Therapeutics will post -0.49 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. The trade was a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 50,000 shares of company stock valued at $1,551,658. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics in the fourth quarter worth approximately $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter valued at about $49,062,000. RA Capital Management L.P. purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth approximately $43,516,000. Darwin Global Management Ltd. bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $23,168,000. Finally, SB Capital Management Inc purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $11,544,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.